Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
Next revision		 Previous revision
eyelash_poliosis [2025/10/07 16:01] – Scott Larsoneyelash_poliosis [2026/05/26 19:12] (current) – [Eyelash Poliosis] Scott Larson
Line 1: Line 1:
 ====== Eyelash Poliosis ====== ====== Eyelash Poliosis ======
-FIXME+
  
 ====Causes==== ====Causes====
Line 11: Line 11:
   * Drug-induced    * Drug-induced 
     * topical prostaglandin F(2α) analogues used for glaucoma, usually reversible poliosis      * topical prostaglandin F(2α) analogues used for glaucoma, usually reversible poliosis 
-  * Halo nevus or other benign nevus-associated poliosis  +  * Skin lesions 
-    * localized whitening of lashes adjacent to a melanocytic nevus.  +    * Cutaneous/ocular malignant melanoma may rarely present with poliosis due to destruction of melanocytes adjacent to a melanoma; biopsy is required for diagnosis 
-  * Phthisis bulbi or chronic uveitis–related poliosis with longstanding ocular inflammation.  +    * Halo nevus or other benign nevus-associated poliosis  
-  * Vogt–Koyanagi–Harada (VKH) disease is a multisystem autoimmune disorder that can present with eyelash poliosis, often accompanied by bilateral granulomatous uveitis, auditory symptoms, and meningeal signs. Diagnosis relies on clinical findings and multimodal imaging, with indocyanine green angiography and enhanced depth imaging OCT being key tools. Sympathetic ophthalmia is a bilateral granulomatous uveitis following ocular trauma or surgery, and may present with poliosis; early recognition and prompt systemic immunosuppression are critical.  +      * localized whitening of lashes adjacent to a melanocytic nevus.  
- +  * Uveitis associated poliosis  
-Cutaneous/ocular malignant melanoma may rarely present with poliosis due to destruction of melanocytes adjacent to a melanoma; biopsy is required for diagnosis, as recommended by the American Academy of Dermatology.[6-8] +    * Phthisis bulbi 
- +    * Vogt–Koyanagi–Harada (VKH) disease  
-Key Additional History and Follow-up Tests: +      * a multisystem autoimmune disorder  
-• History of autoimmune disease, ocular trauma, surgery, or topical medication use. +      * bilateral granulomatous uveitis, auditory symptoms, and meningeal signs. 
-• Associated skin depigmentation, hearing changes, or neurologic symptoms. +    * Sympathetic ophthalmia is a bilateral granulomatous uveitis
-• Slit-lamp examination for uveitis. +
-• Skin and eyelid examination for vitiligo, nevi, or dermatitis. +
-• Consider biopsy of suspicious lesions. +
-• Imaging (OCT, ICGA) if VKH or sympathetic ophthalmia is suspected. +
-• Thyroid and autoimmune panel if systemic disease is suspected. +
- +
-  - Ordered List Item[[https://pubmed.ncbi.nlm.nih.gov/21839315|Vitiligo: A Comprehensive Overview Part I. Introduction, Epidemiology, Quality of Life, Diagnosis, Differential Diagnosis, Associations, Histopathology, Etiology, and Work-Up. Alikhan A, Felsten LM, Daly M, Petronic-Rosic V.   - Journal of the American Academy of Dermatology. 2011;65(3):473-491.]] +
-Atopic Dermatitis. +
-Ständer S. +
- +
-The New England Journal of Medicine. 2021;384(12):1136-1143. doi:10.1056/NEJMra2023911. +
- +
- Leading Journal  +
- +
- +
- +
- +
- +
- +
- +
-4. +
-Topical Prostaglandin F(2alpha) Analog Induced Poliosis. +
-Chen CS, Wells J, Craig JE. +
- +
-American Journal of Ophthalmology. 2004;137(5):965-6. doi:10.1016/j.ajo.2003.11.020. +
- +
- +
- +
- +
- +
-5. +
-Poliosis Circumscripta: Overview and Underlying Causes. +
-Sleiman R, Kurban M, Succaria F, Abbas O. +
- +
-Journal of the American Academy of Dermatology. 2013;69(4):625-33. doi:10.1016/j.jaad.2013.05.022. +
- +
- +
-6. +
-Precise, Simplified Diagnostic Criteria and Optimised Management of Initial-Onset Vogt-Koyanagi-Harada Disease: An Updated Review. +
-Herbort CP, Tugal-Tutkun I, Abu-El-Asrar A, et al. +
- +
-Eye (London, England). 2022;36(1):29-43. doi:10.1038/s41433-021-01573-3. +
- +
- +
-7. +
-Recent Advances in Diagnosis and Management of Sympathetic Ophthalmia. +
-Fromal OV, Swaminathan V, Soares RR, Ho AC. +
- +
-Current Opinion in Ophthalmology. 2021;32(6):555-560. doi:10.1097/ICU.0000000000000803. +
- +
-8. +
-Guidelines of Care for the Management of Primary Cutaneous Melanoma. +
-Swetter SM, Tsao H, Bichakjian CK, et al. +
- +
-Journal of the American Academy of Dermatology. 2019;80(1):208-250. doi:10.1016/j.jaad.2018.08.055.+
  
-Practice Guideline+====Resources==== 
 +  - [[https://pubmed.ncbi.nlm.nih.gov/21839315|Vitiligo: A Comprehensive Overview Part I. Introduction, Epidemiology, Quality of Life, Diagnosis, Differential Diagnosis, Associations, Histopathology, Etiology, and Work-Up. Alikhan A, Felsten LM, Daly M, Petronic-Rosic V.Journal of the American Academy of Dermatology. 2011;65(3):473-491.]] 
 +  - [[https://www.nejm.org/doi/full/10.1056/NEJMra2023911|Atopic Dermatitis.Ständer S. The New England Journal of Medicine. 2021;384(12):1136-1143.]] 
 +  - [[https://pubmed.ncbi.nlm.nih.gov/15126178/|Topical Prostaglandin F(2alpha) Analog Induced Poliosis. Chen CS, Wells J, Craig JE. American Journal of Ophthalmology. 2004;137(5):965-6.]] 
 +  - [[https://pubmed.ncbi.nlm.nih.gov/23850259/|Poliosis Circumscripta: Overview and Underlying Causes. Sleiman R, Kurban M, Succaria F, Abbas O. Journal of the American Academy of Dermatology. 2013;69(4):625-33.]] 
 +  - [[https://pubmed.ncbi.nlm.nih.gov/34145419/|Precise, Simplified Diagnostic Criteria and Optimised Management of Initial-Onset Vogt-Koyanagi-Harada Disease: An Updated Review. Herbort CP, Tugal-Tutkun I, Abu-El-Asrar A, et al. Eye (London, England). 2022;36(1):29-43.]] 
 +  - [[https://pubmed.ncbi.nlm.nih.gov/34494974/|Recent Advances in Diagnosis and Management of Sympathetic Ophthalmia. Fromal OV, Swaminathan V, Soares RR, Ho AC. Current Opinion in Ophthalmology. 2021;32(6):555-560.]] 
 +  - [[https://pubmed.ncbi.nlm.nih.gov/30392755/|Guidelines of Care for the Management of Primary Cutaneous Melanoma. Swetter SM, et al. Journal of the American Academy of Dermatology. 2019;80(1):208-250.]]
  
 {{tag>ddx}} {{tag>ddx}}